 | Up a level |
Matter-Walstra, K W; Achermann, R; Rapold, R; Klingbiel, D; Bordoni, A; Dehler, S; Konzelmann, I; Mousavi, M; Clough-Gorr, Kerri M; Szucs, T; Schwenkglenks, M; Pestalozzi, B C (2017). Days spent in acute care hospitals at the end of life of cancer patients in four Swiss cantons: a retrospective database study (SAKK 89/09). European journal of cancer care, 26(4), e12453. Wiley-Blackwell 10.1111/ecc.12453
Schandelmaier, S; Conen, K; von Elm, E; You, J J; Blümle, A; Tomonaga, Y; Saccilotto, R; Amstutz, A; Bengough, T; Meerpohl, J J; Stegert, M; Olu, K K; Tikkinen, K A O; Neumann, I; Carrasco-Labra, A; Faulhaber, M; Mulla, S M; Mertz, D; Akl, E A; Sun, X; ... (2015). Planning and reporting of quality-of-life outcomes in cancer trials. Annals of oncology, 26(9), pp. 1966-1973. Oxford University Press 10.1093/annonc/mdv283
Lippuner, K; Grifone, S; Schwenkglenks, M; Schwab, P; Popp, A W; Senn, C; Perrelet, Romain (2012). Comparative trends in hospitalizations for osteoporotic fractures and other frequent diseases between 2000 and 2008. Osteoporosis international, 23(3), pp. 829-39. London: Springer-Verlag 10.1007/s00198-011-1660-8
Schwenkglenks, M; Lippuner, Kurt (2007). Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporosis international, 18(11), pp. 1481-1491. London: Springer 10.1007/s00198-007-0390-4
Blum, S; Kuehne, M; Rodondi, Nicolas; Mueller, A; Ammann, P; Moschovitis, G; Kobza, R; Schlaepfer, J; Meyre, P; Bonati, L H; Ehret, G; Sticherling, C; Schwenkglenks, M; Osswald, S; Conen, D (August 2018). 1358 Prevalence of silent vascular brain lesions among patients with atrial fibrillation and no known history of stroke. European Heart Journal, 39(suppl_1), p. 264. Oxford Academic 10.1093/eurheartj/ehy565.1358
